BENGALURU, India, Dec. 8, 2025 /PRNewswire/ -- Parkinson's disease often begins far more quietly than many people realise. Early indicators…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
December 05, 2025 08:00 ET | Source: Amneal Pharmaceuticals LLC Interim data show substantial improvements in “Good On” time compared…
HYDERABAD, India, Nov. 24, 2025 /PRNewswire/ -- In an inspiring story of resilience, medical excellence, and a mother's unconditional love,…
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the…
Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo…
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…
Report highlights emerging biotech innovators advancing new therapies, equity and investment across reproductive, chronic and mental health LONDON, Nov. 13,…
Congenital Heart Disease (CHD) is one of the most common birth defects, affecting approximately 1% of live births globally and…